scholarly journals Evaluation of MR relaxation times following trastuzumab treatment of breast cancer cells in a 3D bioreactor

2020 ◽  
Vol 77 (1) ◽  
pp. 35-41 ◽  
Author(s):  
Dorota Bartusik-Aebisher ◽  
David Aebisher ◽  
Anna Czmil ◽  
Damian Mazur
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Relaxation Times ◽  
Trastuzumab Treatment ◽  
Mr Relaxation

scholarly journals UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells

2021 ◽  
Author(s):  
Jun Hua ◽  
Zhe Zhang ◽  
Lili Zhang ◽  
Yan Sun ◽  
Yuan Yuan
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Neoadjuvant Therapy ◽  
Needle Biopsy ◽  
Breast Cancer Cells ◽  
Her2 Positive ◽  
Trastuzumab Treatment ◽  
Her2 Positive Breast Cancer ◽  
Trastuzumab Therapy ◽  
Positive Breast Cancer

Abstract Purpose This study aimed to investigate the possibility of UCP-2 inhibitor in reducing acquired resistance of trastuzumab to improve the outcome of patients receiving trastuzumab therapy by exploring the relationship between UCP-2 expression and HER2 signaling pathway and examining whether UCP-2 expression was modulated by trastuzumab treatment. Methods 32 women diagnosed with primary HER2-positive breast cancer were recruited in this study. Needle biopsy was obtained from patients before they received at least four cycles neoadjuvant therapy containing trastuzumab in combination with chemotherapy. Surgical tumor biopsy was obtained during surgical procedure after the neoadjuvant therapy. Levels of HER2 phosphorylation and UCP-2 expression were detected by immunohistochemistry (IHC) and compared between tumor needle biopsy tissue and surgical tumor samples of these patients, as well as in BT474 breast cancer cells before and after trastuzumab treatment. HER2-selective phosphorylation/kinase activity inhibitor ONT-380 was used to identify the correlation between HER2 phosphorylation level and UCP-2 expression. UCP-2 inhibitor Genipin was then used to evaluate the apoptosis index in BT474 cells treated with trastuzumab. Results UCP-2 expression was significantly elevated in surgical tumor samples from breast cancer patients receiving trastuzumab in a neoadjuvant setting. We further confirmed our findings in HER2-positive BT474 cell line and found that trastuzumab treatment induced phosphorylation of HER2 and the overexpression of UCP-2, and the latter can be reversed by HER2 selective kinase inhibitor ONT-380. Moreover, UCP-2 inhibitor Genipin significantly enhanced the proliferation suppression effects of trastuzumab and markedly promoted apoptosis. Conclusion Taken together, our study identified UCP-2 as a novel therapeutic target for HER2 positive breast cancer and UCP-2 inhibitor may have great potential to enhance the response rate and efficacy of trastuzumab therapy.

Re-expression of ERalpha in ER negative breast cancer cells following trastuzumab treatment

2011 ◽  
Vol 213 (3) ◽  
pp. S139
Author(s):  
Gemma Solon ◽  
Marie McIlroy ◽  
D. Collins ◽  
Arnold D.K. Hill ◽  
Leonie Young
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Trastuzumab Treatment

scholarly journals Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells

Oncotarget ◽  
2017 ◽  
Vol 8 (36) ◽  
pp. 60109-60122 ◽  
Author(s):  
Paola Bagnato ◽  
Alessia Castagnino ◽  
Katia Cortese ◽  
Maria Bono ◽  
Silvia Grasso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Trastuzumab Treatment ◽  
Signaling Events

scholarly journals Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation

Cancer Cell ◽  
2010 ◽  
Vol 18 (5) ◽  
pp. 423-435 ◽  
Author(s):  
Ke Liang ◽  
Francisco J. Esteva ◽  
Constance Albarracin ◽  
Katherine Stemke-Hale ◽  
Yang Lu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Recombinant Human Erythropoietin ◽  
Breast Cancer Cells ◽  
Trastuzumab Treatment ◽  
Human Erythropoietin ◽  
Src Activation

The proliferation of breast cancer cells are inhibited by the human intrabody targeting cyclinD1

2010 ◽  
Vol 34 (8) ◽  
pp. S49-S49
Author(s):  
Lei Wang ◽  
Xun Zhou ◽  
Lihong Zhou ◽  
Yong Chen ◽  
Xun Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document